Repare Therapeutics Inc
NASDAQ:RPTX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.75
8.41
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Repare Therapeutics Inc
Repare Therapeutics Inc
Cash from Operating Activities
Repare Therapeutics Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Operating Activities
-$127.2m
|
CAGR 3-Years
-176%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Cash from Operating Activities
-CA$7m
|
CAGR 3-Years
-190%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Cash from Operating Activities
-$1.5m
|
CAGR 3-Years
54%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
$28.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Covalon Technologies Ltd
XTSX:COV
|
Cash from Operating Activities
CA$1.2m
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Operating Activities
-CA$8.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
3%
|
|
Repare Therapeutics Inc
Glance View
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 152 full-time employees. The company went IPO on 2020-06-19. The firm is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. The company uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The firm is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.
See Also
What is Repare Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-127.2m
USD
Based on the financial report for Dec 31, 2023, Repare Therapeutics Inc's Cash from Operating Activities amounts to -127.2m USD.
What is Repare Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-59%
The average annual Cash from Operating Activities growth rates for Repare Therapeutics Inc have been -176% over the past three years , -59% over the past five years .
You don't have any saved screeners yet
